• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Type 2 Asthma Learning Hub
    • Atopic Dermatitis Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • Prurigo Nodularis Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region
Rhinology

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

Vibeke Backer and Prof. Sietze Reitsma contribute their insights. Crucially, the symposium will also focus on future directions, including emerging therapies, personalized medicine approaches, and innovative strategies aimed at achieving better disease control and improved patient outcomes in CRSwNP.
Vibeke Backer
Sietze Reitsma
DMSc, MD
Vibeke Backer +1 more
ADVENT at ERS-ISIAN 2025
Past event
23June2025

Agenda

Welcome & Introductions
Vibeke Backer
Type 2 Inflammation: Links With Severe/Uncontrolled CRSwNP
Vibeke Backer
Treatable Traits in CRSwNP
Sietze Reitsma
Regulatory-Approved Biologics for CRSwNP: A Clinical Overview and Update
Sietze Reitsma
Disease Control in CRSwNP
Vibeke Backer
Audience Q&A
All Faculty
Tags
CRSwNPpatient burdendisease severitydisease controltype 2 inflammation
MAT-GLB-2502287 - 1.0 - 06/2025

Speakers

Pulmonology
DMSc, MD

Vibeke Backer

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

Sietze Reitsma
Rhinology
MD, PhD

Sietze Reitsma

ENT and Rhinologist at the University Medical Centres in Amsterdam | Professor at the Department of Otorhinolaryngology and Head and Neck Surgery | University of Amsterdam

Related resources

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
Rhinology
16 min
expert video

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions